Key result
Gene therapy targeting intracellular calcium handling, such as SERCA2a and S100A1, represents a promising investigational treatment option for advanced heart failure.
Gene therapy targeting intracellular calcium transport represents an emerging investigational approach for the treatment of advanced heart failure.
Investigational gene therapies for calcium handling should not yet change practice in advanced HF; leaves open the need for randomized efficacy trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Seong et al. (2009) conducted a review in Heart failure. Gene therapy targeted to intracellular calcium transport was evaluated. Gene therapy targeting intracellular calcium handling, such as SERCA2a and S100A1, represents a promising investigational treatment option for advanced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: